Traws Pharma, Inc.
TRAW
$1.68
-$0.34-16.83%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.79M | 2.85M | 2.90M | 227.00K | 226.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.79M | 2.85M | 2.90M | 227.00K | 226.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 2.79M | 2.85M | 2.90M | 227.00K | 226.00K |
| SG&A Expenses | 8.52M | 9.67M | 11.40M | 11.69M | 12.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.67M | 18.63M | 23.17M | 25.13M | 25.14M |
| Operating Income | -17.88M | -15.79M | -20.27M | -24.90M | -24.91M |
| Income Before Tax | 9.17M | -13.31M | -17.82M | -140.05M | -166.52M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.17 | -13.31 | -17.82 | -140.05 | -166.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.17M | -13.31M | -17.82M | -140.05M | -166.52M |
| EBIT | -17.88M | -15.79M | -20.27M | -24.90M | -24.91M |
| EBITDA | -17.81M | -15.77M | -20.26M | -24.89M | -24.90M |
| EPS Basic | 1.14 | -5.24 | -6.39 | -19.74 | -38.47 |
| Normalized Basic EPS | 1.05 | -4.52 | -9.75 | -12.33 | -17.95 |
| EPS Diluted | 1.06 | -5.32 | -6.47 | -19.82 | -38.48 |
| Normalized Diluted EPS | 0.99 | -4.59 | -9.82 | -12.39 | -17.95 |
| Average Basic Shares Outstanding | 30.96M | 24.69M | 16.83M | 12.33M | 6.21M |
| Average Diluted Shares Outstanding | 31.21M | 24.93M | 17.08M | 12.58M | 6.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |